France asks Roche as it moves toward suggesting off-label use of Avastin; Judge drops pharmacists from Pfizer pay-for-delay suit;

@FiercePharma: Top-read pharma news Thurs--New numbers back old meme: Pharma does spend more on marketing than R&D. Article | Follow @FiercePharma

@EricPFierce: FDA punishes Ranbaxy for plant problems. Snatches away its approval for generic Nexium. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: This week's full issue of FierceVaccines. Subscribe here. | Follow @CarlyHFierce

> France regulators have asked Roche ($RHHBY) for info on off-label uses of its cancer drug Avastin for eye conditions now that the government is going to suggest doctors make the cheaper substitution. Story

> A federal judge in New Jersey have tossed California pharmacists from pay-for-delay suit against Pfizer ($PFE) and Ranbaxy Laboratories over Lipitor. Story (sub. req.)

> The U.K. government is being urged to stand behind a bill that would require it to seek licenses for new uses of off-patent drugs where there is a need. Story

> A European Medicines Agency committee has suggested new measures to reduce the risks of Servier's Ivabradine for chest pain. Story

Medical Device News

@FierceMedDev: ICYMI: Siemens sells hearing aid biz for $2.7B amid rumors it will exit healthcare entirely. Story | Follow @FierceMedDev

@VarunSaxena2: UPDATE: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Google signs onto Foundation Medicine cancer Dx by offering tests to employees. FierceDiagnostics article | Follow @EmilyWFierce

> 'Ambulance drone' for delivering defibrillation could someday save lives. More

> Investigational balloon catheter shows promise in treating peripheral artery disease. Story

> 'Bionic eye' maker Second Sight focused on raising $31.5M in IPO. Article

Biotech News

@FierceBiotech: Intercept shares slide as investigators question OCA's safety/efficacy for NASH. Article | Follow @FierceBiotech

@JohnCFierce: That's a big no to $NVS--FDA advisers spurn Novartis' blood cancer drug, putting approval in doubt. Report | Follow @JohnCFierce

@DamianFierce: A biotech developing a concussion treatment has recruited Brett Favre to help it raise money for R&D, because hey. Release | Follow @DamianFierce

@EmilyMFierce: Hey all, today is my last day at Fierce! Please do keep in touch: emily[dot]mullin[at]gmail[dot]com and @emilylmullin. | Follow @EmilyMFierce

> Avanir's odds for a timely drug approval aren't looking so good. Story

> INC banks $150M in the latest big CRO IPO. Report

> Rockwell clears an FDA hurdle with its dialysis drug. Article

And Finally... Mylan says it has agreement for Walt Disney Parks and Resorts to put up information in its parks and on its cruise ships telling passengers where to get Mylan's Epi-Pens for adults or children in the event someone has anaphylaxis allergic reactions. Release

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.